was a 22%, 15%, and 120% reduction in risk of coronary heart disease at eight weeks, eight months, and four years, respectively, using a multiple logistic function from the London Whitehall study. The reduction in the incidence of new electrocardiographic abnormalities at four years was greater than predicted. This may have been the result of chance variation, but it may suggest that relaxation affects pathways other than the established cardiac risk factors.
Short course chemotherapy for tuberculosis of lymph nodes: a controlled trial BRITISH THORACIC SOCIETY RESEARCH COMMITTEE Abstract One hundred and fifty two patients with tuberculosis of lymph nodes were enrolled in a randomised trial of nine versus 18 months' chemotherapy. The regimens consisted of rifampicin plus isoniazid for nine or 18 months, supplemented initially by ethambutol for eight weeks. At 36 months data from 113 patients were available for analysis, of whom 56 had received the short course regimen. Progress during chemotherapy was uneventful in 84 of the 113 patients. Fresh nodes appeared in 13 patients and existing nodes increased in size in 13; these events occurred within the first eight months of treatment. In 10 patients residual nodes were palpable at the end of chemotherapy. Events including enlarge-Introduction A survey of notifications of tuberculosis in England and Wales in 1978 showed that disease of the lymph nodes was the commonest form of non-respiratory tuberculosis.' The British Thoracic Association's first controlled trial of chemotherapy for tuberculosis of lymph nodes compared two 18 month regimens in 90 patients.2 3 The regimens comprised either rifampicin plus isoniazid or ethambutol plus isoniazid, both supplemented with streptomycin for the first two months. A satisfactory response to chemotherapy was seen, and microbiological relapse did not occur when treatment was stopped. In a retrospective study of lymph node tuberculosis Summers and McNicol reported no relapse in 239 patients, some of whom were treated with nine month regimens incorporating rifampicin and isoniazid. 4 Our study compares treatment with rifampicin and isoniazid given for either nine or 18 months, supplemented initially by eight weeks' treatment with ethambutol. We describe the state of patients 36 months after entry to the study. V shows the progress of the patients after chemotherapy. Progress was entirely satisfactory in 101 patients and events were recorded in 12, seven of whom received the nine month regimen and five the 18 month regimen. In 10 of these 12 patients no events were recorded more than six months after treatment. Two patients who received the short course of treatment and three who received the long course had residual nodes at 36 months. Further chemotherapy was given to two patients who had received the short course.In one patient nodes enlarged three months after treatment, which was restarted by the doctor without any specimens having been obtained. Of the nine other patients whose nodes enlarged, two underwent node biopsy. Discussion Tuberculosis of lymph nodes was reviewed by Campbell and Dyson, who described a prospective controlled trial of two 18 month regimens.2 The population of the present study was similar to that described by Campbell and Dyson in terms of race (predominantly Asian) and sex distribution (predominantly women). The response of lymph nodes to the present regimen was similar to that observed by Campbell and Dyson, who used isoniazid and ethambutol or isoniazid and rifampicin, both regimens being supplemented with streptomycin for the first two months. In 2% of their patients, however, nodes enlarged during the last half of the regimens, a result that we did not observe. Of our patients receiving treatment for 18 months, 3 (500) had residual nodes at the end of treatment compared with 13% in the previous study.
Short course regimens have been assessed prospectively in pulmonary tuberculosis but not tuberculosis of lymph nodes. All the events after chemotherapy in the patients who took the nine month course occurred within six months after the end of treatment, during which time the patients taking the 18 month course were still receiving treatment. During the subsequent 21 months' follow up no further events occurred in those who had taken the short course regimen. After treatment no relapse was recorded microbiologically in the 27 months' follow up of the 56 patients who had taken the nine month regimen or in the 18 months' follow up of the 57 patients who had taken the 18 month regimen. The one patient who was retreated without further histological or microbiological specimens being obtained may have had a true relapse, but results from this and previous studies show that nodes may enlarge and new nodes appear both during and after chemotherapy without indicating a failure of treatment or relapse. These nodes may show histological features characteristic of tuberculosis but be sterile on culture. The enlargement may be due to a reaction to tuberculoprotein. Our study provides no evidence that surgical removal of nodes is advantageous in the treatment of tuberculosis of lymph nodes. Furthermore, an operation is not necessarily indicated for nodes that enlarge after treatment because this enlargement is usually transient.
This report suggests that a nine month regimen comprising rifampicin and isoniazid is adequate treatment for tuberculosis of lymph nodes. A further report will be written when the five year follow up is complete.
